Raymond James & Associates Kintara Therapeutics, Inc. Transaction History

Raymond James & Associates

  • $161 Billion
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 12, 2022
SELL
$0.14 - $0.5 $2,203 - $7,870
-15,740 Closed
0 $0
Q1 2021

May 14, 2021
BUY
$1.32 - $2.74 $20,776 - $43,127
15,740 New
15,740 $27,000

About Kintara Therapeutics, Inc.

KTRA Quotes by TradingView
  • Ticker KTRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 80,807,296
  • Market Cap $17.8M
  • Description
  • Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme,...
More about KTRA
Track This Portfolio

Track Raymond James & Associates Portfolio

Follow Raymond James & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email